Fate Therapeutics INC: directors' dealings · United States · SEC (Form 4)

About Fate Therapeutics INC

Fate Therapeutics, Inc. is a United States biopharmaceutical company listed on NASDAQ and headquartered in San Diego, California (United States). Incorporated in Delaware in 2007, the company has built its identity around first-in-class, off-the-shelf cellular immunotherapies derived from human induced pluripotent stem cells (iPSCs). From an investor’s perspective, Fate is best understood as a platform company rather than a single-asset developer: its value proposition is tied to the ability to industrialize cell therapy manufacturing and broaden access beyond bespoke autologous treatments. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1434316/000095017025033510/fate-20241231.htm?utm_source=openai)) The company’s core technology is what it calls “cell programming.” Fate engineers human iPSCs with synthetic controls of cell function, creates clonal master cell lines, and then differentiates those lines into cellular therapy candidates. The strategic logic is clear: produce standardized, renewable starting material that can support scalable manufacturing and potentially improve consistency versus patient-specific cell therapies. The company also maintains office, laboratory, and GMP manufacturing space at its San Diego headquarters, underscoring its in-house development and manufacturing orientation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1434316/000095017025033510/fate-20241231.htm?utm_source=openai)) Fate’s pipeline is centered on two major therapeutic areas: oncology and autoimmune disease. Its lead program, FT819, is a CD19-targeted CAR T-cell candidate developed from iPSCs and now focused primarily on autoimmune indications such as systemic lupus erythematosus and lupus nephritis. FT522 is an off-the-shelf CD19-targeted CAR NK cell candidate aimed at B cell–mediated autoimmune diseases, while FT836 is a next-generation CAR T program targeting MICA/B in solid tumors. This mix reflects Fate’s effort to create a differentiated portfolio spanning both hematology/autoimmunity and solid tumors. ([fatetherapeutics.com](https://www.fatetherapeutics.com/pipeline/?utm_source=openai)) Competitively, Fate stands out for its proprietary iPSC-based manufacturing platform. That differentiates it from conventional autologous CAR T companies and from allogeneic cell therapy developers relying on donor-derived starting material. The potential upside is a more scalable, accessible therapy model; the trade-off is that clinical and regulatory execution remains the dominant hurdle, and the sector is highly competitive and capital intensive. For equity investors, the investment case is therefore driven less by near-term revenue and more by clinical validation, partnering optionality, and proof that the platform can generate repeatable therapeutic results. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1434316/000095017025033510/fate-20241231.htm?utm_source=openai)) Recent developments have been encouraging from a pipeline-building standpoint. In 2024, the FDA allowed the IND for FT522 in certain B cell–mediated autoimmune diseases. In 2025, Fate reported that FT819 received RMAT designation from the FDA in moderate-to-severe systemic lupus erythematosus, while clinical work continued across FT819 and FT836. The company also disclosed that FT819 studies include sites in the United States, the United Kingdom, and the European Union, which broadens the program’s geographic footprint and signals a move toward more advanced clinical execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1434316/000095017025033510/fate-20241231.htm?utm_source=openai))